Welcome to our dedicated page for WW International news (Ticker: WW), a resource for investors and traders seeking the latest updates and insights on WW International stock.
WW International, Inc. operates the Weight Watchers weight-management platform through digital, workshop and clinical subscription offerings. Company news commonly covers subscriber trends, subscription revenue, adjusted operating measures and the balance between its Behavioral business and its Clinical business.
Recurring updates also include expansion of the Med+ clinical offering, access to FDA-approved GLP-1 treatment options through affiliated medical groups, debt-reduction actions involving its term loan, and governance changes such as board appointments, committee assignments and interim executive-leadership structure.
Weight Watchers (NASDAQ: WW) expanded collaboration with Novo Nordisk to offer Med+ members subscription pricing for Wegovy, promising the lowest available self-pay prices and up to $1,200 annual savings.
Eligible members can pre-pay for 3, 6, or 12 months, with discounts on pens and pills and access to Wegovy across multiple doses.
Weight Watchers (Nasdaq: WW) reported fourth-quarter and full-year 2025 results on March 16, 2026. Q4 total revenue was $163 million, Q4 net loss was $6 million (3.6% margin) and Q4 Adjusted EBITDA was $18 million (11.1% margin). End of period subscribers totaled 2.8 million, including 130,000 clinical subscribers, up 42% year-over-year.
The company exceeded its 2025 revenue and Adjusted EBITDA guidance and provided Q1 2026 subscriber estimates and full-year 2026 guidance: revenue of $620–$635 million and Adjusted EBITDA of $105–$115 million.
Weight Watchers (NASDAQ: WW) released a GLP-1 Results Report showing Med+ members who used the GLP-1 Success Program lost substantially more weight than those on medication alone. Key metrics: 7.4 lb average first-month loss, 21% average weight loss at 12 months, and 20.5% at 24 months. The report also cites improved clinical measures and higher member-reported quality-of-life gains.
The analysis highlights up to 61.3% more weight loss in month one for engaged members and over 30% greater 12-month loss versus select competitors.
WW (NASDAQ: WW) will release fourth-quarter and full-year 2025 results for the period ended December 31, 2025, before market open on Monday, March 16, 2026.
The company will host a conference call at 8:30 a.m. ET that same day and will provide a live webcast and a replay on corporate.ww.com available for at least 90 days.
Weight Watchers (NASDAQ: WW) announced a strategic partnership with PVOLVE on February 10, 2026 to add clinically validated strength, mobility, and stability workouts into Weight Watchers programs. The collaboration integrates PVOLVE classes into Core, Core+, Med+, GLP-1 Success and Menopause tracks, offers a 1,700+ on-demand library at reduced rates, and a curated starter kit. Company data cites Med+ members engaged with the program lost 61.3% more weight at one month and 29.1% more at 12 months versus medication alone; a 12-week PVOLVE program showed 19% improved lower-body strength.
Weight Watchers (NASDAQ: WW) will participate in investor conferences in January 2026, including the ICR Conference in Orlando on January 12–13 and a virtual fireside chat at the CJS Securities 26th Annual New Ideas for the New Year on January 14 at 11:00 a.m. ET.
The January 14 fireside chat will be available via live audio webcast at corporate.ww.com under Events and Presentations, with a replay accessible for at least 90 days. Weight Watchers said it will host investor meetings during these events.
Weight Watchers described its offering as an integrated, science-backed weight management system for the GLP-1 era, combining clinical interventions, access to GLP-1 medications when clinically appropriate, technology, and coaching. For investor inquiries, contacts were provided.
Weight Watchers (NASDAQ: WW) announced on January 5, 2026 that its Med+ integrated GLP-1 platform will offer access to FDA‑approved oral Wegovy® pill, expanding options beyond injectable therapies. The program pairs medication access with behavioral coaching, clinician care, and digital tools.
Weight Watchers said Med+ members can access the oral Wegovy pill starting at $149 per month. Internal member analyses reported that engaged Med+ members on GLP-1s lost 61.3% more body weight at 1 month and 29.1% more at 12 months versus GLP-1 users without behavioral support. The company is a NovoCare® Recognized Care Provider and emphasized combining medication with structured support to improve real-world outcomes.
Weight Watchers (NASDAQ: WW) launched a fully integrated platform for the GLP-1 era on Dec. 16, 2025, combining a medical program, behavioral support, coaching, community, and new digital tools.
Key elements include Weight Watchers Med+ (board-certified physicians prescribing GLP-1s for eligible members), the standalone GLP-1 Success Program, a redesigned app with Weight Health Score, an AI Body Scanner, premium fitness content, and flexible Modes (All-In, Lose, Maintain). The rollout begins Dec. 26, 2025.
WeightWatchers (Nasdaq: WW) reported Q3 fiscal 2025 results for the quarter ended September 30, 2025: End of period subscribers 3.0 million (including Clinical subscribers 124k), Total revenues $172 million, and Clinical subscription revenue $26 million, up 35.3% YoY. The company recorded a net loss of $58 million (net loss margin 33.4%), which included a $53 million income tax charge. Adjusted EBITDA was $43 million (margin 24.9%).
Balance sheet improved: total debt reduced by >70% (~$1.1 billion) and cash rose to $170 million. Management narrowed fiscal 2025 guidance to Revenues $695–700M and Adjusted EBITDA $145–150M.
WW (NASDAQ: WW) will release third quarter 2025 results for the period ended September 30, 2025 before market open on Thursday, November 6, 2025.
The company will host a conference call at 8:30 a.m. ET on November 6, 2025, with a live webcast available on the company's investor site at corporate.ww.com under Events and Presentations. A replay of the webcast will be available on the site for at least 90 days.